ethyl-6-methyl-3-oxooctanoate | 212481-76-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl-6-methyl-3-oxooctanoate
• 英文别名: Ethyl 6-methyl-3-oxooctanoate
• CAS: 212481-76-0
• 化学式: C₁₁H₂₀O₃
• 分子量: 200.278
• InChiKey: ZJYXKFMWHWKZJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl-6-methyl-3-oxooctanoate 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以50%的产率得到
  参考文献：
  名称：

  Antimicrobial Peptides with Potential for Biofilm Eradication: Synthesis and Structure Activity Relationship Studies of Battacin Peptides

  摘要：

  We report on the first chemical syntheses and structureactivity analyses of the cyclic lipopeptide battacin which revealed that conjugation of a shorter fatty acid, 4-methyl-hexanoic acid, and linearization of the peptide sequence improves antibacterial activity and reduces hemolysis of mouse blood cells. This surprising finding of higher potency in linear lipopeptides than their cyclic counterparts is economically beneficial. This novel lipopeptide was membrane lytic and exhibited antibiofilm activity against Pseudomonas aeruginosa, Staphylococcus aureus, and, for the first time, Pseudomonas syringe pv. actinidiae. The peptide was unstructured in aqueous buffer and dimyristoylphosphatidylcholine-polymerized diacetylene vesicles, with 12% helicity induced in 50% v/v of trifluoroethanol. Our results indicate that a well-defined secondary structure is not essential for the observed antibacterial activity of this novel lipopeptide. A truncated pentapeptide conjugated to 4-methyl hexanoic acid, having similar potency against Gram negative and Gram positive pathogens was identified through alanine scanning.

  DOI：

  10.1021/jm501084q
• 作为产物：
  描述：

  ethyl potassium malonate 在 N,N'-羰基二咪唑 、 magnesium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 ethyl-6-methyl-3-oxooctanoate
  参考文献：
  名称：

  Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia

  摘要：

  具有通式（I）的一种化合物： 或其药学上可接受的盐、溶剂化合物、酯或互变异构体，其中： Q选自以下群组： 和 L选自以下群组： 或其药学上可接受的盐、溶剂化合物、酯或互变异构体，可用于治疗代谢综合征和血脂异常等疾病、疾患或症状。

  公开号：

  US20060264489A1

文献信息

• Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 3. Discovery of a Potent, 2-Nonaryl, Highly Selective ET_A Antagonist (A-216546)
  作者：Gang Liu、Kenneth J. Henry,、Bruce G. Szczepankiewicz、Martin Winn、Natasha S. Kozmina、Steven A. Boyd、James Wasicak、Thomas W. von Geldern、Jinshyun R. Wu-Wong、William J. Chiou、Douglas B. Dixon、Bach Nguyen、Kennan C. Marsh、Terry J. Opgenorth

  DOI：10.1021/jm980217s

  日期：1998.8.1

  was replaced by an n-pentyl group, the resultant antagonist 3 exhibited substantially increased ETB/ETA activity ratio, but a decreased ETA affinity. Structure-activity studies revealed that substitution and geometry of this alkyl group, and substitution on the benzodioxolyl ring, are important in optimizing this series of highly ETA selective antagonists. In particular, the combination of a (E)-2,2-dimethyl-3-pentenyl

  以前，我们已经报道了ABT-627（1，A-147627，A-127722的活性对映体）的发现，这是一种基于2，4-二芳基取代的吡咯烷-3-羧酸的内皮素受体A拮抗剂。该化合物以0. 034 nM的亲和力（Ki）结合ETA受体，并且对ETA受体的选择性是ETB受体的2000倍。为了进一步提高ETA选择性，我们在本系列文章中扩展了结构活性研究。当1的对-茴香基基团被正戊基基团取代时，所得拮抗剂3表现出显着提高的ETB / ETA活性比，但降低的ETA亲和力。结构活性研究表明，该烷基的取代和几何形状以及在苯并二氧戊环上的取代对于优化这一系列高度ETA选择性拮抗剂很重要。特别地，（E）-2，2-二甲基-3-戊烯基和7-甲氧基-1，3-苯并二恶唑-5-基的组合提供了对人ETA受体亚型具有亚纳摩尔亲和力的疏水化合物10b。 ETB / ETA活性比超过130000。同时，在合成烯烃化合物的过程中，发现
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Palani Anandan

  公开号：US20080019978A1

  公开（公告）日：2008-01-24

  The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

  本发明提供了式（I）的化合物及其药学上可接受的盐，溶剂化合物，酯和互变异构体，其中： Q选自以下组： L选自以下组： 本发明还提供了包含一种或多种式（I）化合物的药学组合物以及使用式（I）化合物的方法。
• Nitrogen-containing heterocyclic compounds and methods of use thereof
  申请人：Palani Anandan

  公开号：US20070066630A1

  公开（公告）日：2007-03-22

  The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

  本发明提供了式（I）化合物及其药学上可接受的盐、溶剂化合物、酯和互变异构体，其中：Q选自以下组：L选自以下组：包括一种或多种式（I）化合物的药学组合物，以及使用式（I）化合物的方法。
• Peptide antibiotics
  申请人：THE UNIVERSITY OF QUEENSLAND

  公开号：US11279733B2

  公开（公告）日：2022-03-22

  There is provided a range of novel compounds. These novel compounds may demonstrate abroad spectrum antibacterial and antifungal activity. These compounds may be active against the emerging polymyxin resistant bacteria. These compounds may also be useful when used in conjunction with other pharmaceutically active agents.

  本文提供了一系列新型化合物。这些新型化合物可显示出国外光谱的抗菌和抗真菌活性。这些化合物对新出现的多粘菌素耐药菌具有活性。这些化合物与其他药物活性剂一起使用时也可能很有用。
• ORTHO-CONDENSED 2-PYRIDINONE DERIVATIVES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1885726B1

  公开（公告）日：2016-12-14